폐선암 치료 시장, 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Lung Adenocarcinoma Treatment Market expanded to USD 5.1 billion in 2023 and will grow at 10.5% CAGR from 2024 to 2032, driven by the rising incidence of lung cancer, particularly lung adenocarcinoma. Increasing rates of smoking, pollution, and genetic predispositions contribute to this upward trend. Also, innovations in targeted therapies enhance treatment effectiveness and patient outcomes, addressing specific genetic mutations associated with adenocarcinoma. These advancements provide more personalized treatment options and lead to improved survival rates. As awareness of these therapies grows, they attract more patients, further expanding the market size in this critical area.

The lung adenocarcinoma treatment industry is fragmented based on treatment type, stages of disease, end-use, and region.

The chemotherapy segment will reach USD 1.9 billion in 2023 and grow at a 10.2% CAGR through 2032, fueled by its widespread use in managing advanced stages of the disease. Chemotherapy remains a standard treatment, often utilized alone or in combination with other therapies like immunotherapy or targeted treatments. Its effectiveness in reducing tumor size and controlling disease progression, even in cases where other treatments fail, solidifies its leading position. Increased accessibility and advancements in drug formulations further bolster the growth of this segment in the market.

The hospitals segment will secure USD 3.2 billion by 2024 and achieve a 6.3% CAGR from 2024 to 2032, owing to the availability of advanced diagnostic and treatment facilities. Hospitals are often the primary centers for administering complex therapies such as chemotherapy, radiation, and targeted treatments. Additionally, the presence of specialized healthcare professionals and the ability to manage severe cases contribute to the segment's dominance. The growing number of lung cancer patients and improved healthcare infrastructure further drive the demand for hospital-based treatments in this market.

North America lung adenocarcinoma treatment market will capture USD 5.7 billion by 2032, attributed to a well-established healthcare infrastructure and high prevalence of lung cancer cases. The region benefits from advanced medical technologies, innovative treatment options, and strong investment in cancer research. Also, rising awareness about early diagnosis and improved access to healthcare services enhance treatment outcomes. Favorable reimbursement policies and an increasing aging population further propel market growth, making North America a key contributor to the global lung adenocarcinoma treatment industry.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of lung adenocarcinoma
    • 3.2.1.2 Advances in precision medicine and targeted therapies
    • 3.2.1.3 Rising awareness and early detection programs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatments
    • 3.2.2.2 Adverse effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Surgery
• 5.3 Radiation therapy
• 5.4 Chemotherapy
• 5.5 Targeted therapy
• 5.6 Immunotherapy
• 5.7 Other treatment types

Chapter 6 Market Estimates and Forecast, By Stage of Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Stage I and II
• 6.3 Stage III
• 6.4 Stage IV

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AbbVie Inc.
• 9.2 Amgen Inc.
• 9.3 AstraZeneca PLC
• 9.4 Boehringer Ingelheim International GmbH
• 9.5 Bristol-Myers Squibb Company
• 9.6 Celgene Corporation
• 9.7 Eli Lilly and Company
• 9.8 F. Hoffmann-La Roche Ltd
• 9.9 GlaxoSmithKline plc
• 9.10 Johnson and Johnson Services, Inc.
• 9.11 Merck and Co., Inc.
• 9.12 Novartis AG
• 9.13 Pfizer Inc.
• 9.14 Sanofi S.A.
• 9.15 Takeda Pharmaceutical Company Limited